<DOC>
	<DOCNO>NCT02822482</DOCNO>
	<brief_summary>The study consist two distinct sequential part : - A Phase Ib aim determine MTD ( Maximum Tolerated Dose ) combination ( copanlisib/cetuximab ) RP2D - A Phase II aim evaluate efficacy combination RP2D ( Recommended Phase 2 Dose ) All patient treat Copanlisib , selective PI3KCA inhibitor , association Cetuximab .</brief_summary>
	<brief_title>Copanlisib Association With Cetuximab Patients With Recurrent and/or Metastatic Head Neck Squamous Cell Carcinomas Harboring PI3KCA Mutation/Amplification and/or PTEN Loss</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>1 . Patients R/M HNSCC ( oropharynx , oral cavity , hypopharynx larynx ) , histologically cytologically confirm , amenable curative treatment surgery and/or chemotherapy and/or radiotherapy ( Stage III/IV ) 2 . Adult men woman ≥ 18 year 3 . Patients ECOG performance status 0 2 ( ECOG : Eastern Cooperative Oncology Group ) 4 . Patients tumor harbor PI3K mutation/amplification and/or PTEN loss 5 . Patients radiologic documented progression relapse cetuximab therapy ( patient could either receive combination platinum doublet cetuximab cetuximab platinum doublet ) 6 . Patients prior platinum base therapy , unless contraindicate 7 . Patients least one measurable lesion assess Magnetic Resonance Imaging ( MRI ) computerize tomography scanner ( CTscan ) accord RECIST 1.1 . Patients must clinically and/or radiographically document measurable disease . At least one site disease must unidimensionally measurable follow CTscan , physical exam ≥ 10 mm Lymph node short axis ≥ 15 mm Tumor measurement must perform within 28 day prior start study drug . 8 . Women childbearing potential men must agree use adequate contraception sexually active . This apply since sign informed consent form 12 month ( woman child bear potential ) 6 month ( fertile men ) last study drug administration ( Copanlisib ) . Highly effective contraception method detailed section 7.2 . 9 . Women childbearing age sexually active female patient reproductive potential must negative pregnancy test ( serum urine within 7 day prior start study drug ) . 10 . Provision sign date , write informed consent prior study specific procedure , sample analysis 11 . Patients social insurance coverage 12 . Glomerular filtration rate ( GFR ) ≥ 40 mL/min/1.73 m² accord Modification Diet Renal Disease ( MDRD ) abbreviate formula ( within 7 day prior start study drug ) . If target , evaluation may repeat least 24 hour either accord MDRD abbreviate formula 24 hour sampling . If later result within acceptable range , may use fulfill inclusion criterion instead . 1 . Patients previously treat PI3K and/or mTOR inhibitor 2 . Patients anticancer therapy ( radiotherapy , immunotherapy , chemotherapy , etc . ) within 28 day investigational treatment within 28 day prior initiation study drug treatment , unless evidence progression since last treatment 3 . Patients currently use approve investigational antineoplasic agent 4 . Patients uncontrolled arterial hypertension despite optimal medical management , Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 , Unstable angina ( angina symptom rest ) , newonset angina ( begin within last 3 month ) . Myocardial infarction le 6 month start test drug No active cardiac disease include follow : left ventricular ejection fraction ( LVEF ) &lt; 50 % determined Multiple Gated Acquisition ( MUGA ) scan echocardiogram ( ECHO ) QTc &gt; 470 m screen ECG 5 . Patients uncontrolled diabetes mellitus ( patient control Type I II diabetes mellitus eligible phase II study fast HbA1c ≤ 8.5 % screening ) 6 . Patients history Human Immunodeficiency Virus ( HIV ) Hepatitis B ( HBV ) hepatitis C ( HCV ) infection . All patient must screen HIV , HBV HCV 28 day prior first dose use routine virus laboratorial panel . Patients positive HBs Ag HBc Ab eligible negative HBVDNA . Patients positive antiHCV antibody eligible negative HCVRNA 7 . Patients active uncontrolled symptomatic central nervous system ( CNS ) metastasis . Patients eligible disease control least 30 day corticosteroid prior start study drug . 8 . Patients major surgery within 28 day , open biopsy within 7 day , prior start study drug . Patients must recover major side effect surgery . 9 . Patients receive medication substance inhibitor inducer CYP3A4 ineligible . Copanlisib primarily metabolize CYP3A4 . Therefore concomitant use strong inhibitor CyP3A4 ( e.g. , ketoconazole , itraconazole , clarithromycin , ritonavir , indinavir , nelfinavir saquinavir ) , inducer CYP3A ( e.g . rifampin , phenytoin , carbamazepine , phenobarbital , st. John 's Wort ) permit Day 14 Cycle 1 Safety follow visit . 10 . Patients alter hematopoietic organ function , indicate follow criterion ( assess within 7 day prior first dose ) : Absolute granulocyte &lt; 1.0 ×109/L Platelets &lt; 75 x 109/L ALAT/ASAT &gt; 2.5 x ULN absence &gt; 5x ULN presence liver metastases Bilirubin &gt; 1.5 x ULN ( except Gilbert Syndrome : &lt; 3.0 mg/dL ) Creatinine clearance &lt; 60 mL/min ( measure calculate Cockcroft Gault formula ) serum creatinine &gt; 1.0 x ULN Lipase &gt; 1.5 x ULN INR PTT &gt; 1.5 x ULN 11 . Patients history hypersensitivity monoclonal antibody active inactive excipients study drug 12 . Known drug alcohol abuse 13 . Known underlying medical condition , investigator 's opinion , would make administration study drug hazardous patient obscure interpretation toxicity determination adverse event 14 . History uncontrolled seizure , seizure disorder require medication , central nervous system disorder psychiatric disability judge investigator clinically significant , preclude informed consent , interfere compliance oral drug intake 15 . Unwillingness give write informed consent , unwillingness participate , inability comply protocol duration study 16 . Individuals deprive liberty place authority tutor 17 . Previous concurrent history malignancy within 5 year prior study treatment except curatively treat : Cervical carcinoma situ Nonmelanoma skin cancer Superficial bladder cancer ( Ta [ noninvasive tumor ] , Tis [ carcinoma situ ] T1 [ tumor invades lamina propria ] ) Localized prostate cancer 18 . Patients evidence history bleed diathesis . Any hemorrhage bleeding event ≥ CTCAE Grade 3 within 4 week prior start study medication 19 . Proteinuria ≥ CTCAE Grade 3 assess 24h protein quantification estimate urine proteincreatinine ratio &gt; 3.5 random urine sample 20 . History concurrent condition interstitial lung disease severity and/or severely impaired lung function ( judged investigator ) 21 . Concurrent diagnosis pheochromocytoma 22 . Pregnant breastfeeding patient . Women childbearing potential must serum pregnancy test perform maximum 7 day start treatment , negative result must document start treatment . 23 . Unresolved toxicity high CTCAE Grade 1 attribute prior therapy/procedure , exclude alopecia 24 . Ongoing immunosuppressive therapy 25 . Blood platelet transfusion le 7 day start treatment 26 . Myeloid growth factor within 14 day prior treatment 27 . Systemic continuous corticosteroid therapy daily dose high 15 mg prednisone equivalent allow . Previous corticosteroid therapy must stop reduce allow dose 7 day perform screen CT scan/MRI , whichever perform first , prior first study drug administration . If patient chronic corticosteroid therapy , corticosteroid deescalated maximum allow dose patient sign IC . Patients may use topical inhaled corticosteroid . 28 . History receive allogeneic bone marrow organ transplant 29 . Antiarrhythmic therapy ( beta blocker digoxin permit )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>